

Supplementary Table 5. Cox regression analysis of subgroups associated with TTP of (A) entire cohort, (B) SNUH subcohort, and (C) SNUBH subcohort between the CHB and non-CHB groups after IPTW
(A) Entire cohort

| Variables | Events/Subjects | | CHB (vs. non-CHB) | | P [†] _{interaction} |
|--------------------------|---------------------|--------------------------|--------------------------|---------|---------------------------------------|
| | CHB group (n=82) | Non-CHB group (n=846) | Adjusted HR* (95% CI) | P-value | |
| Sex | | | | | 0.47 |
| Female | (n=396) 10/29 | 108/367 | 0.79 (0.40–1.57) | 0.50 | |
| Male | (n=532) 6/53 | 145/479 | 0.23 (0.10–0.51) | <0.001 | |
| Age | | | | | 0.38 |
| ≤60 years | (n=387) 8/48 | 91/339 | 0.25 (0.12–0.52) | <0.001 | |
| >60 years | (n=541) 8/34 | 162/507 | 0.61 (0.31–1.20) | 0.15 | |
| Ann Arbor classification | | | | | 0.42 |
| Early (I–II) | (n=392) 2/22 | 56/256 | 0.47 (0.12–1.84) | 0.28 | |
| Advanced (III–IV) | (n=536) 14/60 | 197/590 | 0.42 (0.24–0.74) | 0.003 | |
| LDH | | | | | 0.16 |
| Normal (≤225 IU/L) | (n=500) 10/53 | 73/447 | 0.57 (0.28–1.14) | 0.11 | |
| Elevated (>225 IU/L) | (n=428) 6/29 | 180/399 | 0.29 (0.13–0.61) | 0.001 | |
| Underlying liver status | | | | | 0.001 |
| No cirrhosis | (n=872) 11/72 | 237/800 | 0.33 (0.18–0.61) | <0.001 | |
| Cirrhosis | (n=56) 5/10 | 16/46 | 1.70 (0.58–4.95) | 0.33 | |
| IPI risk | | | | | 0.007 |
| Low/Low-intermediate | (n=770) 10/65 | 182/705 | 0.37 (0.19–0.74) | 0.004 | |
| High/High-intermediate | (n=158) 6/17 | 71/141 | 0.44 (0.21–0.93) | 0.03 | |
| Subtype of DLBCL | | | | | 0.01 |
| GCB | (n=340) 5/29 | 71/311 | 0.56 (0.23–1.38) | 0.21 | |
| Non-GCB | (n=537) 11/50 | 169/487 | 0.38 (0.20–0.70) | <0.001 | |
| BM involvement | | | | | 0.01 |
| No | (n=708) 11/59 | 155/649 | 0.63 (0.34–1.20) | 0.16 | |
| Yes | (n=154) 4/19 | 37/135 | 0.12 (0.05–0.33) | <0.001 | |
| Extranodal involvement | | | | | 0.87 |
| No | (n=265) 4/20 | 59/245 | 0.99 (0.34–2.87) | 0.99 | |
| Yes | (n=663) 12/62 | 194/601 | 0.34 (0.19–0.59) | <0.001 | |

Supplementary Table 5. Continued
(B) SNUH subcohort

| Variables | Events/Subjects | | CHB (vs. non-CHB) | | P [†] _{interaction} |
|--------------------------|------------------|-----------------------|-----------------------|---------|---------------------------------------|
| | CHB group (n=67) | Non-CHB group (n=542) | Adjusted HR* (95% CI) | P-value | |
| Sex | | | | | 0.13 |
| Female | (n=267) | 69/242 | 0.94 (0.40–2.23) | 0.89 | |
| Male | (n=342) | 87/300 | 0.29 (0.12–0.70) | 0.006 | |
| Age | | | | | 0.35 |
| ≤60 years | (n=285) | 68/250 | 0.31 (0.11–0.84) | 0.02 | |
| >60 years | (n=324) | 88/292 | 0.81 (0.39–1.72) | 0.59 | |
| Ann Arbor classification | | | | | 0.56 |
| Early (I–II) | (n=278) | 1/22 | 0.28 (0.06–1.30) | 0.10 | |
| Advanced (III–IV) | (n=331) | 12/45 | 0.51 (0.27–0.96) | 0.04 | |
| LDH | | | | | 0.49 |
| Normal (≤225 IU/L) | (n=352) | 8/47 | 0.60 (0.26–1.41) | 0.24 | |
| Elevated (>225 IU/L) | (n=257) | 5/20 | 0.43 (0.17–1.09) | 0.08 | |
| Underlying liver status | | | | | 0.15 |
| No cirrhosis | (n=555) | 9/58 | 0.36 (0.18–0.72) | 0.004 | |
| Cirrhosis | (n=54) | 4/9 | 3.46 (0.11–112.5) | 0.48 | |
| IPI risk | | | | | 0.98 |
| Low/Low-intermediate | (n=451) | 7/50 | 0.58 (0.23–1.47) | 0.25 | |
| High/High-intermediate | (n=158) | 6/17 | 0.60 (0.27–1.34) | 0.22 | |
| Subtype of DLBCL | | | | | 0.23 |
| GCB | (n=226) | 5/21 | 1.29 (0.40–4.15) | 0.67 | |
| Non-GCB | (n=346) | 8/43 | 0.37 (0.18–0.79) | 0.01 | |
| BM involvement | | | | | 0.11 |
| No | (n=495) | 9/49 | 0.70 (0.34–1.46) | 0.34 | |
| Yes | (n=88) | 4/14 | 0.22 (0.07–0.75) | 0.01 | |
| Extranodal involvement | | | | | 0.42 |
| No | (n=189) | 3/15 | 1.71 (0.46–6.43) | 0.99 | |
| Yes | (n=420) | 10/52 | 0.42 (0.22–0.79) | 0.01 | |

BM, bone marrow; CHB, chronic hepatitis B; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell; HR, hazard ratio; IPI, International Prognostic Index; IPTW, inverse probability of treatment weighting; LDH, lactate dehydrogenase; SNUH, Seoul National University Hospital; SNUBH, Seoul National University Bundang Hospital.

*Adjusted for sex, age, Ann Arbor classification, LDH, cirrhosis, extranodal involvement, IPI risk, BM involvement, and classified subtype.

[†]P_{interaction} was calculated between the CHB and non-CHB groups.

Supplementary Table 5. Continued
(B) SNUH subcohort

| Variables | Events/Subjects | | CHB (vs. non-CHB) | | P [†] _{interaction} |
|--------------------------|------------------|-----------------------|-----------------------|---------|---------------------------------------|
| | CHB group (n=15) | Non-CHB group (n=304) | Adjusted HR* (95% CI) | P-value | |
| Sex | | | | | 0.24 |
| Female | (n=131) | 41/127 | 0.49 (0.02–10.85) | 0.65 | |
| Male | (n=188) | 56/177 | 0.26 (0.05–1.41) | 0.12 | |
| Age | | | | | |
| ≤60 years | (n=128) | 33/113 | | | |
| >60 years | (n=191) | 64/191 | | | 0.06 |
| Ann Arbor classification | | | | | |
| Early (I–II) | (n=114) | 1/3 | 2.74 (0.75–10.02) | 0.13 | |
| Advanced (III–IV) | (n=205) | 2/12 | 0.17 (0.04–0.76) | 0.02 | |
| LDH | | | | | 0.03 |
| Normal (≤225 IU/L) | (n=148) | 2/6 | 7.37 (0.93–58.47) | 0.06 | |
| Elevated (>225 IU/L) | (n=171) | 1/9 | 0.07 (0.01–0.31) | <0.001 | |
| Underlying liver status | | | | | |
| No cirrhosis | (n=317) | 2/14 | | | |
| Cirrhosis | (n=2) | 1/1 | | | |
| IPI risk | | | | | |
| Low/Low-intermediate | (n=316) | 3/15 | | | |
| High/High-intermediate | (n=3) | 0/0 | | | |
| Subtype of DLBCL | | | | | |
| GCB | (n=114) | 0/8 | | | |
| Non-GCB | (n=191) | 3/7 | | | |
| BM involvement | | | | | |
| No | (n=213) | 2/10 | | | |
| Yes | (n=66) | 1/5 | | | |
| Extranodal involvement | | | | | 0.96 |
| No | (n=76) | 1/5 | 0.21 (0.04–1.13) | 0.07 | |
| Yes | (n=243) | 2/10 | 0.21 (0.02–2.00) | 0.17 | |

BM, bone marrow; CHB, chronic hepatitis B; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell; HR, hazard ratio; IPI, International Prognostic Index; IPTW, inverse probability of treatment weighting; LDH, lactate dehydrogenase; SNUH, Seoul National University Hospital; SNUBH, Seoul National University Bundang Hospital.

*Adjusted for sex, age, Ann Arbor classification, LDH, cirrhosis, extranodal involvement, IPI risk, BM involvement, and classified subtype.
[†]P_{interaction} was calculated between the CHB and non-CHB groups.

[†]In cases where patients could not be allocated to subgroups, making multivariable analysis and P for interaction statistically incomputable, the corresponding cells were left blank.